Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The objective was to determine if hepatitis C virus (HCV) infection or mild to severe hepatic
impairment (Child-Pugh Classes A, B, and C) altered the PK of buprenorphine,
norbuprenorphine, or naloxone.
Phase:
Phase 4
Details
Lead Sponsor:
Indivior Inc.
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Diphenhydramine Naloxone Promethazine